JP Morgan Initiates Coverage On Alamar Biosciences with Overweight Rating, Announces Price Target of $30

Alamar Biosciences, Inc.

Alamar Biosciences, Inc.

ALMR

0.00

JP Morgan analyst Casey Woodring initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Overweight rating and announces Price Target of $30.